Ranibizumab and aflibercept: Intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 11, 2015, Pages 6501-6505

  Niwa, Yuichi ^a   Kakinoki, Masashi ^a   Sawada, Tomoko ^a   Wang, Xiying ^a,b   Ohji, Masahito ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Aflibercept; Ranibizumab; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DATA PROCESSING; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE TIME; LIMIT OF DETECTION; MACACA; MALE; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; VITRECTOMY; ANIMAL; AQUEOUS HUMOR; DISEASE MODEL; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; METABOLISM; PATHOLOGY; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; AQUEOUS HUMOR; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTRAVITREAL INJECTIONS; MACACA; MACULAR DEGENERATION; MALE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 84944089141     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-17279     Document Type: Article

References (25)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
2. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99:11393–11398.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444.
5. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65.
6. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548.
7. Moreno SF, Paloma JB. Therapeutic anti-VEGF in age-related macular degeneration: ranibizumab and bevacizumab controversy. Br J Ophthalmol. 2008;92:866–867.
8. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29:313–318.
9. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IVadministered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113: 1522.e1-e4.
10. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116:2141–2148.e1.
11. Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011;118:1089–1097.
12. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010;51:1606–1608.
13. Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci. 2012;53:5877–5880.
14. Christoforidis JB, Williams MM, Wang J, et al. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina. 2013; 33:946.
15. Ahn SJ, Ahn J, Park S, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2014;55:567–573.
16. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46:726–733.
17. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154:682–686. e682.
18. Stewart MW. What are the half-lives of ranibizumab and aflibercept (Trap-eyeVEGF) in human eyes? Calculations with a mathematical model. Eye Reports. 2011;1:5.
19. Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology. 1985;92:1601–1605.
20. Jarus G, Blumenkranz M, Hernandez E, Sossi N. Clearance of intravitreal fluorouracil: normal and aphakic vitrectomized eyes. Ophthalmology. 1985;92:91–96.
21. Ahn J, Kim H, Woo SJ, et al. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther. 2013;29:612–618.
22. Group CR. Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med. 2011;364:1897.
23. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185.
24. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92:667–668.
25. Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol. 2014;158:738–744. e731.